Dr. Pierre Salim Najm, M.D.

Consultant Endocrinologist

Dr. Pierre Salim Najm, M.D.

Consultant Endocrinologist

Dr. Pierre Salim Najm - Consultant Endocrinologist

Department: Endocrinology
Specialties: Endocrinology, Diabetes and Metabolism
Interests: Glands, Hormone Disorders, thyroid diseases and osteoporosis
Languages: Arabic, French and English




BOOK AN APPOINTMENT


Dr. Pierre Najm graduated from Georgetown University School of Medicine in Washington D.C. in 1992 and completed his Internal Medicine residency and Endocrinology fellowship at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania in 1997.

After completion of his training and American Board certification Dr. Najm returned to his home country Lebanon where he was Assistant Professor of Medicine and Chief of the Division of Endocrinology at St. George University Hospital. During that time he was also involved in teaching medical students and residents as well as initiating the Endocrinology fellowship program. In 2007 he relocated to Abu Dhabi where he has been practicing at Imperial College London Diabetes Centre.

Dr. Najm treats all types of general adult endocrine conditions but has a special interest in thyroid diseases and osteoporosis. He is licensed to practice medicine in Abu Dhabi, Lebanon, and Pennsylvania.

He is fluent in Arabic, French and English. He also knows basic Italian and German.


  • Education & Trainings
  • Organizations
  • Lectures & Conferences
  • Research & Publications

FELLOWSHIP : Division of Endocrinology, Diabetes, and Metabolic Diseases
Department of Medicine – Thomas Jefferson University Hospital, Philadelphia, PA – USA

RESIDENCY : Internal Medicine
Department of Medicine – Thomas Jefferson University Hospital, Philadelphia, PA – USA

M.D. Georgetown University School of Medicine
Washington, DC – USA

M.S. (Physiology), Georgetown University
Washington, DC – USA

B.S. (Biology), American University of Beirut
Beirut, Lebanon

  • OSTEOS (founding member)
    (Member of the Executive Committee, April 2006 – April 2007)
  • Lebanese Society of Diabetology
  • Lebanese Society of Endocrinology, Diabetology, and Lipidology
    (Member of the Executive Committee, July 2002 – July 2006)
  • American Association of Clinical Endocrinologists
  • American Diabetes Association
  • Pennsylvania Medical Society
  • Type 2 Diabetes: From Prevention to Treatment, January 2007. Beirut, Lebanon.
  • Prevention of Diabetes in High-Risk Patients: The Role of Antihypertensives, May 2006. Beirut, Lebanon.
  • Glucose Intolerance in the Mentally Ill, May 2006. Cairo, Egypt.
  • Treatment of Postprandial Hyperglycemia: Point – Counterpoint, April 2006. Beirut, Lebanon.
  • Management of Insulin Resistance in Type 2 Diabetes Mellitus, February 2006. Dbayeh, Lebanon.
  • Screening, Diagnosis, and Management of Type 2 Diabetes, Pharmacists Congress, February 2006. Beirut, Lebanon.
  • Is There a Metabolic Syndrome? February 2006. Beirut, Lebanon.
  • Inpatient Hyperglycemia: Do We Need to Treat? January 2006. Zahle, Lebanon.
  • Effective Strategies to Improve Glycemic Control in Type II Diabetes, January 2006. Tripoli, Lebanon.
  • Metabolic Syndrome Case Discussion, December 2005. Beirut, Lebanon.
  • When and How to Treat Postmenopausal Osteoporosis, May 2005.
  • Paphos/Larnaca, Cyprus and Beirut, Lebanon.
  • Management of Hypertension and Albuminuria in Diabetes, May 2005. Beirut, Lebanon.
  • Clinical Use of Recombinant Human PTH in the Management of Postmenopausal Osteoporosis, May 2005. Limassol/Larnaca, Cyprus.
  • When and How to Treat Postmenopausal Osteoporosis, April 2005. Valletta, Malta.
  • Clinical Use of Recombinant Human PTH in the Management of Postmenopausal Osteoporosis, April 2005. Valletta, Malta and Al-Ain, UAE.
  • Managing Endocrine Issues in the Mentally Ill, March 2005. Dbayeh, Lebanon.
  • Insulin Therapy in Hospitalized Patients, February 2005. Amman, Jordan.
  • Lebanese Guidelines on Osteoporosis. Presentation to the Lebanese Society of Endocrinology, January 2005. Beirut, Lebanon.
  • Cholesterol Lowering – A critical Consideration in Patients with Diabetic Dyslipidemia, December 2004. Dubai/AbuDhabi, UAE.
  • Inpatient Hyperglycemia: Do We Need to Treat ? First Annual Scientific Meeting of the Syrian, Iraqi, Lebanese, and Jordanian Diabetes Associations, November 2004. Aleppo, Syria.
  • Prevention of Fractures in Postmenopausal Osteoporosis, June 2004. St. George Hospital, Beirut, Lebanon.
  • Prevention of Fractures in Postmenopausal Osteoporosis, Internal Medicine Congress, May 2004. Tehran, Iran.
  • New Alternatives in the Management of Insulin Resistance in Type II Diabetes, April 2004. Kuwait City, Kuwait.
  • Prevention of Fractures in Postmenopausal Osteoporosis, March 2004. Beirut, Lebanon and Larnaca/Paphos, Cyprus.
  • Inpatient Hyperglycemia: Do We Need to Treat ? March 2004. Beirut, Lebanon.
  • Management of Benign Multinodular Goiter, February 2004. Surgery Congress, Haroun Hospital, Lebanon.
  • New Alternatives in the Management of Insulin Resistance in Type II Diabetes, January 2004. Abu Dhabi/Dubai, UAE.
  • Role of Metformin in the Treatment and Prevention of Type II Diabetes, January 2004. St. George Hospital, Beirut, Lebanon.
  • Managing Type 2 Diabetes in General Practice, December 2003. Lebanese – Order of Physicians, Beirut, Lebanon.
  • Prevention of Diabetic Nephropathy, November 2003. World Diabetes Day, Beirut, Lebanon.
  • Clinical Outcomes in Postmenopausal Women, October 2003. OB-GYN Congress, Tehran, Iran.
  • Clinical Outcomes in Postmenopausal Women – Looking Beyond the Bone, September 2003. PanArab Rheumatology Congress, Beirut, Lebanon.
  • Treatment of Dyslipidemia in Type 2 Diabetes – Insights from the HPS, September 2003. Beirut, Lebanon.
  • Management of Hypertension in Type 2 Diabetes – Evidence Based Medicine, August 2003. Beirut, Lebanon.
  • Management of Diabetes in Hospitalized Patients, May 2003. Crete, Greece.
  • The role of Fluvastatin ER in dyslipidemias: focus on diabetics. May 2003. Beirut, Lebanon.
  • Clinical Issues in the Management of Postmenopausal Osteoporosis, March/April/May 2003. Beirut, Lebanon.
  • Management of Diabetes in Hospitalized Patients, February 2003. Beirut, Lebanon.
  • Clinical Issues in the Management of Postmenopausal Osteoporosis, December 2002. Larnaca/Paphos, Cyprus.
  • Glucose Intolerance in the Mentally Ill, November 2002. Istanbul, Turkey.
  • Glucose Intolerance in the Mentally Ill, October 2002. Beirut, Lebanon.
  • Selection of Therapy in Postmenopausal Osteoporosis, June 2002. Amman, Jordan.
  • Selection of Therapy in Postmenopausal Osteoporosis, June 2002. St. George Hospital, Beirut, Lebanon.
  • The role of Fluvastatin ER in dyslipidemias: focus on diabetics. May 2002. St. George Hospital, Beirut, Lebanon.
  • Cardiovascular Outcomes in Postmenopausal Women. March 2002. Istanbul, Turkey.
  • Effets Extra-osseux du Raloxifène, January 2002. Algiers, Algeria.
  • Selection of Therapy in Postmenopausal Osteoporosis, November 2001. Valletta, Malta.
  • Selection of Therapy in Postmenopausal Osteoporosis, November 2001. Hotel-Dieu de France, Beirut, Lebanon.
  • Clinical Implications of Postprandial Hyperglycemia, October 2001. PanArab Endocrinology Congress, Damascus, Syria.
  • Diabetes and Hypertension, October 2001. Batroun, Lebanon.
  • SERMS: from Clinical Trials to Clinical Practice, June 2001. Tripoli, Lebanon.
  • Prevention and treatment of Postmenopausal Osteoporosis. Trad Hospital, February 2001. Beirut, Lebanon.
  • Thyroid Disease in Pregnancy, December 2000. St. George’s Hospital, Beirut, Lebanon.
  • Postprandial Hyperglycemia: Needs for Better Control, November 2000. Dubai/Abu Dhabi, UAE.
  • Reduction of Hypoglycemia with Insulin Analogs. Pan Arab Endocrinology Congress, October 2000. Amman, Jordan.
  • Raloxifene in the Treatment of Postmenopausal Osteoporosis, October 2000. Damascus, Syria.
  • Round Table Discussion on Diabetes with Lebanese, Syrian, and Jordanian Endocrinologists, May 2000. Limassol, Cyprus.
  • Prevention and Treatment of Osteoporosis. Dubai Pharmaceutical and Industrial Technology Scientific Meeting, November 1999. Dubai, UAE.
  • Role of Lispro in Type I and Type II Diabetes, November 1999. Kuwait City, Kuwait.
  • Clinical Experience with Raloxifene, November 1999. Kuwait City, Kuwait.
  • Raloxifene: A New Choice for Postmenopausal Women’s Health, July 1999. Beirut, Lebanon and La Valletta, Malta.
  • Implications of the UKPDS study, March 1999. Beirut, Lebanon.
  • Round Table Discussion on Diabetes with Lebanese Endocrinologists, March 1999. Beirut, Lebanon.
  • Implications of the UKPDS study. February 1999. Damascus, Syria.
  • Raloxifene, A New Choice for Postmenopausal Women’s Health, Pan Arab Pharmacy Congress, October 1998. Jbeil, Lebanon.
  • Participated as principal investigator in the following clinical trials :
    • Hyperglycemia and its Effect after Acute Myocardial Infarction on Cardiovascular Outcomes in Patients with Type 2 Diabetes (HEART2D).
    • A Trial comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects with Uncontrolled Blood Sugar (ATLANTUS study).
  • Participated as co-investigator in the following clinical trials :
    • A 14-Week Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pregabalin (150-600 mg/day) Using a Flexible, Optimized Dose Schedule in Patients with Painful Diabetic Neuropathy.
    • PRECOSE : Resolution of Optimal Titration to Enhance Current Therapies.
    • A 52-Week, Multicenter, Controlled, Randomized, Open Clinical Trial Comparing HOE901 Insulin with NPH Human Insulin in Subjects with Type I Diabetes.
  • Participated as sub-investigator in the following clinical trials :
    • A Placebo-Controlled Safety and Efficacy Study of Pimagidine in Diabetic Patients with Overt Nephropathy.
    • Repaglinide in Type II Diabetes : A Placebo-Controlled, Double-Blind, Randomized, Six Month Fixed Dose Safety Study.
    • A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multidose Study of the Safety & Pharmacokinetic/Pharmacodynamic Effects of rhIGF-I in Combination with Insulin for treatment of NIDDM.
    • A Phase IIIA, Randomized, Double-Blind, Placebo-Controlled, Multicenter Comparison Study to Evaluate the Safety, Efficacy, and Tolerability of BRL49635C Therapy when Administered to patients with NIDDM.
    • A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Measuring the Effects of Troglitazone with or without Insulin on reaching a Treatment Target in NIDDM Patients Requiring Insulin.
    • A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Multidose Study of the Combined Effects of Subcutaneously Administered Insulin and rhIGF-I in Subjects with IDDM.
    • A 26-Week, Randomized, Double-Blind, Double-Dummy,Multicentered Study to Evaluate the Efficacy, Safety and Tolerability of BRL49635C when Administered to Patients with NIDDM Who Are Inadequately Controlled on a Maximal Dose (20mg/day) of Glyburide.

WHAT PATIENTS SAY ABOUT DR. PIERRE

REVIEW DR. PIERRE ON GOOGLE


Opening Hours


Monday – Saturday
8:00 am – 8:00 pm

Sunday
Family Hub(GP)
Physiotherapy
Dental Clinic



Harley Street Abu Dhabi JCI




Subscribe


Sign up with your mobile number to be the first to know about our latest offers & discounts.




    Copyright © Harley Street Medical Centre 2024 | MOH : HX7WC25Y-160724 16/07/2025

    CALL
    026133999
    ONLINE
    APPOINTMENT
    ONLINE
    Appointment
    BOOK AN APPOINTMENT
    ONLINE
    Appointment
    Scan the code